Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05361668 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
A Phase 2 study, sponsored by Crinetics Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT05361668 is a Phase 2 study that has completed, run by Crinetics Pharmaceuticals. The registered enrollment target is 36 participants.
The verdict
NCT05361668, a Phase 2 study, has completed, sponsored by Crinetics Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and exploratory dose response of paltusotine treatment in subjects with carcinoid syndrome. This study consists of a Randomized Treatment Phase followed by an Open-Label Extension (OLE) Phase.
Interventions
- DRUG Randomized: 40 mg Paltusotine
- DRUG Randomized: 80 mg Paltusotine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2022-04-22 |
| Est. Completion | 2026-02-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05361668
The ClinicalTrials.gov registry entry for NCT05361668 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Crinetics Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Randomized: 40 mg Paltusotine is the first listed.
NCT05361668 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05361668 about?
NCT05361668 is a clinical study titled "Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome". The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and exploratory dose response of paltusotine treatment in subjects with carcinoid syndrome. This study consists of a Randomized Treatment Phase followed by an Open-Label Extension (OLE) Phase.
What is the current status of trial NCT05361668?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2022-04-22. Estimated completion is 2026-02-24.
What interventions are being tested in trial NCT05361668?
The interventions under investigation include: Randomized: 40 mg Paltusotine (DRUG), Randomized: 80 mg Paltusotine (DRUG).
Who is sponsoring clinical trial NCT05361668?
This trial is sponsored by Crinetics Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.